Frequent Occurrence of P53 Gene Mutations in Uterine Cancers at Advanced Clinical Stage and with Aggressive Histological Phenotypes

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1992 Nov 1

PMID 1336492

Citations 6

Authors

H Tsuda

S Hirohashi

Affiliations

Soon will be listed here.

Abstract

The clinical and pathological significance of mutation of the p53 tumor-suppressor gene was examined in 108 cases of primary uterine cancers using single-strand conformation polymorphism and direct DNA sequencing analyses. Mutation of the p53 gene was detected in 19 (31%) of 62 cases of cancer of the uterine corpus and was more frequent in groups at an advanced clinical stage and/or with aggressive histology. Among four adenocarcinomas arising in the lowest portion of the uterine corpus, three showed integration of human papillomavirus (HPV) types 16 and/or 18 DNA, and two of them also showed p53 mutation. In cancer of the uterine cervix, p53 mutations were rare; 7% (3/46) in total, 3% (1/30) of cases with integration of HPV types 16 and/or 18 DNA and 13% (2/16) of cases without HPV DNA integration. Three mutations were detected among two cases at clinical stage IV and two cases of undifferentiated cervical carcinoma. Immunohistochemically, all five cases of uterine cancer which showed diffuse (> 50% of cancer cells) nuclear staining of p53 protein also carried the p53 mutation. Therefore, p53 alterations were suggested to be involved in the development of uterine cancers showing aggressive biological behavior. Although a high incidence of HPV DNA integration and a low incidence of p53 mutation were confirmed in cancer of the uterine cervix, there was no inverse association between integration of HPV types 16 and/or 18 DNA and p53 mutation.

Citing Articles

Abnormal p53 High-Grade Endometrioid Endometrial Cancer: A Systematic Review and Meta-Analysis.

Casanova J, Babiciu A, Duarte G, da Costa A, Serra S, Costa T Cancers (Basel). 2025; 17(1).

PMID: 39796669 PMC: 11718986. DOI: 10.3390/cancers17010038.

Fluorescence in situ hybridization detection of chromosome 7 and/or 17 polysomy as a prognostic marker for cholangiocarcinoma.

Deenonpoe R, Sa-Ngiamwibool P, Watcharadetwittaya S, Thanee M, Intuyod K, Kongpan T Sci Rep. 2022; 12(1):8441.

PMID: 35589822 PMC: 9119972. DOI: 10.1038/s41598-022-11945-8.

Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.

Helland A, Karlsen F, Due E, Holm R, Kristensen G, Borresen-Dale A Br J Cancer. 1998; 78(1):69-72.

PMID: 9662253 PMC: 2062929. DOI: 10.1038/bjc.1998.444.

Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix.

Tenti P, Pavanello S, Padovan L, Spinillo A, Vesentini N, Zappatore R Am J Pathol. 1998; 152(4):1057-63.

PMID: 9546366 PMC: 1858254.

Prognostic value of p53 protein accumulation in cancer cell nuclei in adenocarcinoma of the uterine cervix.

Tsuda H, Jiko K, Tsugane S, Yajima M, Yamada T, Tanemura K Jpn J Cancer Res. 1995; 86(11):1049-53.

PMID: 8567395 PMC: 5920623. DOI: 10.1111/j.1349-7006.1995.tb03019.x.

References

Jenkins J, Chumakov P, Addison C, Sturzbecher H, Wade-Evans A . Two distinct regions of the murine p53 primary amino acid sequence are implicated in stable complex formation with simian virus 40 T antigen. J Virol. 1988; 62(10):3903-6. PMC: 253543. DOI: 10.1128/JVI.62.10.3903-3906.1988. View

Iggo R, Gatter K, Bartek J, Lane D, Harris A . Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990; 335(8691):675-9. DOI: 10.1016/0140-6736(90)90801-b. View

Baker S, Preisinger A, Jessup J, Paraskeva C, Markowitz S, WILLSON J . p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990; 50(23):7717-22. View

Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J . Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer. 1990; 46(5):839-44. DOI: 10.1002/ijc.2910460515. View

Levine A, Momand J, Finlay C . The p53 tumour suppressor gene. Nature. 1991; 351(6326):453-6. DOI: 10.1038/351453a0. View

Abeler V, Kjorstad K . Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol. 1990; 39(3):266-71. DOI: 10.1016/0090-8258(90)90250-o. View

Orita M, Suzuki Y, Sekiya T, Hayashi K . Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989; 5(4):874-9. DOI: 10.1016/0888-7543(89)90129-8. View

Reich N, Levine A . Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature. 1984; 308(5955):199-201. DOI: 10.1038/308199a0. View

Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K . Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342(6250):705-8. DOI: 10.1038/342705a0. View

10.

Gyllensten U, Erlich H . Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. Proc Natl Acad Sci U S A. 1988; 85(20):7652-6. PMC: 282250. DOI: 10.1073/pnas.85.20.7652. View

11.

Salazar O, DePapp E, Bonfiglio T, Feldstein M, Rubin P, Rudolph J . Adenosquamous carcinoma of the endometrium. An entity with an inherent poor prognosis?. Cancer. 1977; 40(1):119-30. DOI: 10.1002/1097-0142(197707)40:1<119::aid-cncr2820400121>3.0.co;2-9. View

12.

Hiyoshi H, Matsuno Y, Kato H, Shimosato Y, Hirohashi S . Clinicopathological significance of nuclear accumulation of tumor suppressor gene p53 product in primary lung cancer. Jpn J Cancer Res. 1992; 83(1):101-6. PMC: 5918648. DOI: 10.1111/j.1349-7006.1992.tb02358.x. View

13.

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

14.

Suzuki Y, Sekiya T, Hayashi K . Allele-specific polymerase chain reaction: a method for amplification and sequence determination of a single component among a mixture of sequence variants. Anal Biochem. 1991; 192(1):82-4. DOI: 10.1016/0003-2697(91)90188-y. View

15.

Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A . Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol. 1988; 8(2):531-9. PMC: 363177. DOI: 10.1128/mcb.8.2.531-539.1988. View

16.

Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H . A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J. 1984; 3(5):1151-7. PMC: 557488. DOI: 10.1002/j.1460-2075.1984.tb01944.x. View

17.

Durst M, Gissmann L, Ikenberg H, zur Hausen H . A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A. 1983; 80(12):3812-5. PMC: 394142. DOI: 10.1073/pnas.80.12.3812. View

18.

Sturzbecher H, Maimets T, Chumakov P, Brain R, Addison C, Simanis V . p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene. 1990; 5(6):795-81. View

19.

Banks L, Matlashewski G, Crawford L . Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem. 1986; 159(3):529-34. DOI: 10.1111/j.1432-1033.1986.tb09919.x. View

20.

Ng A, REAGAN J . Incidence and prognosis of endometrial carcinoma by histologic grade and extent. Obstet Gynecol. 1970; 35(3):437-43. View